Industry Research Reports
Global Rare Neurodegenerative Disease Treatment Market Insights, Forecast to 2030
Industry: Pharma & Healthcare
Published Date: 2024-04-25
Pages: 106 Pages
Report ld: 3072314
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Rare Neurodegenerative Disease Treatment Market Size(US$)
CAGR 2024-2030
6%
Market Size,2030
USD 84,450
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global Rare Neurodegenerative Disease Treatment market is projected to grow from US$ 59530 million in 2024 to US$ 84450 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.0% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Rare Neurodegenerative Disease Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Rare Neurodegenerative Disease Treatment, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Rare Neurodegenerative Disease Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Rare Neurodegenerative Disease Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Rare Neurodegenerative Disease Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Rare Neurodegenerative Disease Treatment sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer, GlaxoSmithKline, Hoffmann-La Roche, Allergan, Merck KGaA, Johnson and Johnson, Pfizer, Novartis and Sanofi, etc.
MARKET SEGMENTATION
By Company
- Bayer
- GlaxoSmithKline
- Hoffmann-La Roche
- Allergan
- Merck KGaA
- Johnson and Johnson
- Pfizer
- Novartis
- Sanofi
- Teva Pharmaceuticals
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Neurotransmitter Agents
- Neuroprotective Agents
- Biologics
- Others
Segment by Application
- Amyotrophic Lateral Sclerosis (ALS)
- Attention Deficit Hyperactivity Disorder (ADHD)
- Alzheimer’s Disease
- Parkinson’s Disease
- Others
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Rare Neurodegenerative Disease Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Rare Neurodegenerative Disease Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Neurodegenerative Disease Treatment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Rare Neurodegenerative Disease Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Rare Neurodegenerative Disease Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Neurotransmitter Agents
1.2.3 Neuroprotective Agents
1.2.4 Biologics
1.2.5 Others
1.3 Market by Application
1.3.1 Global Rare Neurodegenerative Disease Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Amyotrophic Lateral Sclerosis (ALS)
1.3.3 Attention Deficit Hyperactivity Disorder (ADHD)
1.3.4 Alzheimer’s Disease
1.3.5 Parkinson’s Disease
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Rare Neurodegenerative Disease Treatment Sales Estimates and Forecasts 2019-2030
2.2 Global Rare Neurodegenerative Disease Treatment Revenue by Region
2.2.1 Global Rare Neurodegenerative Disease Treatment Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2019-2024)
2.2.3 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2025-2030)
2.2.4 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Region (2019-2030)
2.3 Global Rare Neurodegenerative Disease Treatment Sales Estimates and Forecasts 2019-2030
2.4 Global Rare Neurodegenerative Disease Treatment Sales by Region
2.4.1 Global Rare Neurodegenerative Disease Treatment Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Rare Neurodegenerative Disease Treatment Sales by Region (2019-2024)
2.4.3 Global Rare Neurodegenerative Disease Treatment Sales by Region (2025-2030)
2.4.4 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Rare Neurodegenerative Disease Treatment Sales by Manufacturers
3.1.1 Global Rare Neurodegenerative Disease Treatment Sales by Manufacturers (2019-2024)
3.1.2 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Rare Neurodegenerative Disease Treatment in 2023
3.2 Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturers
3.2.1 Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturers (2019-2024)
3.2.2 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Rare Neurodegenerative Disease Treatment Revenue in 2023
3.3 Global Key Players of Rare Neurodegenerative Disease Treatment, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Rare Neurodegenerative Disease Treatment Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Rare Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Rare Neurodegenerative Disease Treatment, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Rare Neurodegenerative Disease Treatment, Product Offered and Application
3.8 Global Key Manufacturers of Rare Neurodegenerative Disease Treatment, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Rare Neurodegenerative Disease Treatment Sales by Type
4.1.1 Global Rare Neurodegenerative Disease Treatment Historical Sales by Type (2019-2024)
4.1.2 Global Rare Neurodegenerative Disease Treatment Forecasted Sales by Type (2025-2030)
4.1.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2019-2030)
4.2 Global Rare Neurodegenerative Disease Treatment Revenue by Type
4.2.1 Global Rare Neurodegenerative Disease Treatment Historical Revenue by Type (2019-2024)
4.2.2 Global Rare Neurodegenerative Disease Treatment Forecasted Revenue by Type (2025-2030)
4.2.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Rare Neurodegenerative Disease Treatment Price by Type
4.3.1 Global Rare Neurodegenerative Disease Treatment Price by Type (2019-2024)
4.3.2 Global Rare Neurodegenerative Disease Treatment Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Rare Neurodegenerative Disease Treatment Sales by Application
5.1.1 Global Rare Neurodegenerative Disease Treatment Historical Sales by Application (2019-2024)
5.1.2 Global Rare Neurodegenerative Disease Treatment Forecasted Sales by Application (2025-2030)
5.1.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2019-2030)
5.2 Global Rare Neurodegenerative Disease Treatment Revenue by Application
5.2.1 Global Rare Neurodegenerative Disease Treatment Historical Revenue by Application (2019-2024)
5.2.2 Global Rare Neurodegenerative Disease Treatment Forecasted Revenue by Application (2025-2030)
5.2.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Rare Neurodegenerative Disease Treatment Price by Application
5.3.1 Global Rare Neurodegenerative Disease Treatment Price by Application (2019-2024)
5.3.2 Global Rare Neurodegenerative Disease Treatment Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Rare Neurodegenerative Disease Treatment Market Size by Type
6.1.1 US & Canada Rare Neurodegenerative Disease Treatment Sales by Type (2019-2030)
6.1.2 US & Canada Rare Neurodegenerative Disease Treatment Revenue by Type (2019-2030)
6.2 US & Canada Rare Neurodegenerative Disease Treatment Market Size by Application
6.2.1 US & Canada Rare Neurodegenerative Disease Treatment Sales by Application (2019-2030)
6.2.2 US & Canada Rare Neurodegenerative Disease Treatment Revenue by Application (2019-2030)
6.3 US & Canada Rare Neurodegenerative Disease Treatment Market Size by Country
6.3.1 US & Canada Rare Neurodegenerative Disease Treatment Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Rare Neurodegenerative Disease Treatment Sales by Country (2019-2030)
6.3.3 US & Canada Rare Neurodegenerative Disease Treatment Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Rare Neurodegenerative Disease Treatment Market Size by Type
7.1.1 Europe Rare Neurodegenerative Disease Treatment Sales by Type (2019-2030)
7.1.2 Europe Rare Neurodegenerative Disease Treatment Revenue by Type (2019-2030)
7.2 Europe Rare Neurodegenerative Disease Treatment Market Size by Application
7.2.1 Europe Rare Neurodegenerative Disease Treatment Sales by Application (2019-2030)
7.2.2 Europe Rare Neurodegenerative Disease Treatment Revenue by Application (2019-2030)
7.3 Europe Rare Neurodegenerative Disease Treatment Market Size by Country
7.3.1 Europe Rare Neurodegenerative Disease Treatment Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Rare Neurodegenerative Disease Treatment Sales by Country (2019-2030)
7.3.3 Europe Rare Neurodegenerative Disease Treatment Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Rare Neurodegenerative Disease Treatment Market Size
8.1.1 China Rare Neurodegenerative Disease Treatment Sales (2019-2030)
8.1.2 China Rare Neurodegenerative Disease Treatment Revenue (2019-2030)
8.2 China Rare Neurodegenerative Disease Treatment Market Size by Application
8.2.1 China Rare Neurodegenerative Disease Treatment Sales by Application (2019-2030)
8.2.2 China Rare Neurodegenerative Disease Treatment Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Rare Neurodegenerative Disease Treatment Market Size by Type
9.1.1 Asia Rare Neurodegenerative Disease Treatment Sales by Type (2019-2030)
9.1.2 Asia Rare Neurodegenerative Disease Treatment Revenue by Type (2019-2030)
9.2 Asia Rare Neurodegenerative Disease Treatment Market Size by Application
9.2.1 Asia Rare Neurodegenerative Disease Treatment Sales by Application (2019-2030)
9.2.2 Asia Rare Neurodegenerative Disease Treatment Revenue by Application (2019-2030)
9.3 Asia Rare Neurodegenerative Disease Treatment Sales by Region
9.3.1 Asia Rare Neurodegenerative Disease Treatment Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Rare Neurodegenerative Disease Treatment Revenue by Region (2019-2030)
9.3.3 Asia Rare Neurodegenerative Disease Treatment Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Market Size by Type
10.1.1 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Market Size by Application
10.2.1 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Sales by Country
10.3.1 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Rare Neurodegenerative Disease Treatment Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Bayer Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Recent Developments
11.3 Hoffmann-La Roche
11.3.1 Hoffmann-La Roche Company Information
11.3.2 Hoffmann-La Roche Overview
11.3.3 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Hoffmann-La Roche Recent Developments
11.4 Allergan
11.4.1 Allergan Company Information
11.4.2 Allergan Overview
11.4.3 Allergan Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Allergan Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Allergan Recent Developments
11.5 Merck KGaA
11.5.1 Merck KGaA Company Information
11.5.2 Merck KGaA Overview
11.5.3 Merck KGaA Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Merck KGaA Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merck KGaA Recent Developments
11.6 Johnson and Johnson
11.6.1 Johnson and Johnson Company Information
11.6.2 Johnson and Johnson Overview
11.6.3 Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Johnson and Johnson Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Overview
11.7.3 Pfizer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Pfizer Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Pfizer Recent Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Overview
11.8.3 Novartis Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Novartis Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis Recent Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Overview
11.9.3 Sanofi Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Sanofi Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sanofi Recent Developments
11.10 Teva Pharmaceuticals
11.10.1 Teva Pharmaceuticals Company Information
11.10.2 Teva Pharmaceuticals Overview
11.10.3 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Teva Pharmaceuticals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Rare Neurodegenerative Disease Treatment Industry Chain Analysis
12.2 Rare Neurodegenerative Disease Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Rare Neurodegenerative Disease Treatment Production Mode & Process
12.4 Rare Neurodegenerative Disease Treatment Sales and Marketing
12.4.1 Rare Neurodegenerative Disease Treatment Sales Channels
12.4.2 Rare Neurodegenerative Disease Treatment Distributors
12.5 Rare Neurodegenerative Disease Treatment Customers
13 Market Dynamics
13.1 Rare Neurodegenerative Disease Treatment Industry Trends
13.2 Rare Neurodegenerative Disease Treatment Market Drivers
13.3 Rare Neurodegenerative Disease Treatment Market Challenges
13.4 Rare Neurodegenerative Disease Treatment Market Restraints
14 Key Findings in The Global Rare Neurodegenerative Disease Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 66140 million in 2025 and is projected to reach US$ 98880 million, growing at a CAGR of 6.0% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 129
USD 3950.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Research Report 2026
The global Rare Neurodegenerative Disease Treatment market was valued at US$ 66140 million in 2025 and is anticipated to reach US$ 98880 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
Published Date: 2026-04-21
Pages: 116
USD 2900.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Rare Neurodegenerative Disease Treatment market is projected to grow from US$ 62750 million in 2024 to US$ 93810 million by 2031, at a CAGR of 6.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-25
Pages: 138
USD 4900.00
(Single User License)
Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 109
USD 3950.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Rare Neurodegenerative Disease Treatment market size was US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 77
USD 4250.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Research Report 2025
The global market for Rare Neurodegenerative Disease Treatment was valued at US$ 62750 million in the year 2024 and is projected to reach a revised size of US$ 93810 million by 2031, growing at a CAGR of 6.0% during the forecast period.
Published Date: 2025-02-21
Pages: 84
USD 2900.00
(Single User License)
Global Rare Neurodegenerative Disease Treatment Market Research Report 2024
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published Date: 2024-02-07
Pages: 91
USD 2900.00
(Single User License)
Rare Neurodegenerative Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published Date: 2024-01-11
Pages: 121
USD 3950.00
(Single User License)
Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 66140 million in 2025 and is projected to reach US$ 98880 million, growing at a CAGR of 6.0% from 2026 to 2032.
Published: 2026-07-09
Pages: 129
USD 3950.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Research Report 2026
The global Rare Neurodegenerative Disease Treatment market was valued at US$ 66140 million in 2025 and is anticipated to reach US$ 98880 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
Published: 2026-04-21
Pages: 116
USD 2900.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Rare Neurodegenerative Disease Treatment market is projected to grow from US$ 62750 million in 2024 to US$ 93810 million by 2031, at a CAGR of 6.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-25
Pages: 138
USD 4900.00 (Single User License)Rare Neurodegenerative Disease Treatment- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rare Neurodegenerative Disease Treatment was estimated to be worth US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 109
USD 3950.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Rare Neurodegenerative Disease Treatment market size was US$ 62750 million in 2024 and is forecast to a readjusted size of US$ 93810 million by 2031 with a CAGR of 6.0% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 77
USD 4250.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Research Report 2025
The global market for Rare Neurodegenerative Disease Treatment was valued at US$ 62750 million in the year 2024 and is projected to reach a revised size of US$ 93810 million by 2031, growing at a CAGR of 6.0% during the forecast period.
Published: 2025-02-21
Pages: 84
USD 2900.00 (Single User License)Global Rare Neurodegenerative Disease Treatment Market Research Report 2024
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published: 2024-02-07
Pages: 91
USD 2900.00 (Single User License)Rare Neurodegenerative Disease Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
Published: 2024-01-11
Pages: 121
USD 3950.00 (Single User License)
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now